SCHEMBL9320548

SCHEMBL9320548

O=C(O)CCCOc1ccccc1[N+](=O)[O-]

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.70
RAB9A P51151 4/20 0.70
RECQL P46063 2/20 0.70
ALDH1A1 P00352 6/20 0.60
KMT2A Q03164 3/20 0.60
MEN1 O00255 2/20 0.60
KDM4E B2RXH2 5/20 0.58
POLB P06746 2/20 0.58
KCNH2 Q12809 1/20 0.58
HTT P42858 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
LMNA P02545 1/20 0.55
PKM P14618 1/20 0.54
STAT1 P42224 1/20 0.54
CYP2D6 P10635 2/20 0.53
CYP2C19 P33261 2/20 0.53
SENP8 Q96LD8 1/20 0.52
SENP7 Q9BQF6 1/20 0.52
SENP6 Q9GZR1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8164415 1.00 NPC1 (0.70) NPC1RAB9ARECQLALDH1A1KMT2A
SCHEMBL27633714 0.94 NPC1 (0.66) NPC1RAB9ARECQLALDH1A1KMT2A
SCHEMBL4867096 0.92 RAB9A (0.72) NPC1RAB9ARECQLALDH1A1KMT2A
SCHEMBL4867102 0.92 RAB9A (0.72) NPC1RAB9ARECQLALDH1A1KMT2A
SCHEMBL9642715 0.85 NPC1 (0.89) NPC1RAB9ARECQLALDH1A1KMT2A
SCHEMBL7308438 0.83 NPC1 (0.48) NPC1RAB9ARECQLALDH1A1KMT2A
SCHEMBL9187561 0.83 NPC1 (1.00) NPC1RAB9ARECQLALDH1A1KMT2A
Hydrochloric Acid SCHEMBL7306474 0.82 NPC1 (0.47) NPC1RAB9ARECQLALDH1A1KMT2A
SCHEMBL7343243 0.82 NPC1 (0.77) NPC1RAB9ARECQLALDH1A1KMT2A
SCHEMBL1613946 0.82 ALDH1A1 (0.74) NPC1RAB9ARECQLALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0576603-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN MERCK & CO. INC. (US) 1994-01-05 EP disclosed
WO-1992018132-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR MERCK & CO., INC. (US) 1992-10-29 WO disclosed
WO-1992016213-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN MERCK & CO., INC. (US) 1992-10-01 WO disclosed
WO-1992016233-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN MERCK & CO., INC. (US) 1992-10-01 WO disclosed